Free tool
Drug Trial Radar: Rare and genetic disease
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
15
Recruiting, industry sponsors, Rare and genetic disease, Phase 1
By trial status
The same filters, counted in each status. Pick one to switch.
15 trials
Showing 1 to 15, recently updated first.
JCR Pharmaceuticals Co., Ltd.Industry
NCT07640984 · 12 participants (planned) · Start Sep 9, 2026 · Primary completion Jun 30, 2028
Drug: JR-446 · For: Mucopolysaccharidosis IIIB
Sites: Oakland, California; Pittsburgh, Pennsylvania; Fairfax, Virginia · 5 sites in all
Denali Therapeutics Inc.Industry
NCT07354724 · 32 participants (planned) · Start May 12, 2026 · Primary completion Aug 2028
Drug: DNL952 · For: Late-onset Pompe Disease
Sites: Irvine, California; St Louis, Missouri; Durham, North Carolina · 8 sites in all
Solid Biosciences Inc.Industry
NCT07180355 · 10 participants (planned) · Start Oct 22, 2025 · Primary completion Mar 21, 2028
Drug: SGT-212 · For: Friedreich's Ataxia (FA)
Sites: Los Angeles, California; Columbus, Ohio; Philadelphia, Pennsylvania
Kyowa Kirin Co., Ltd.Industry
NCT06525636 · 39 participants (planned) · Start Oct 9, 2024 · Primary completion Jun 14, 2030
Drug: KK8123 · For: X-linked Hypophosphatemia
Sites: San Francisco, California; New Haven, Connecticut; Indianapolis, Indiana · 10 sites in all
Denali Therapeutics Inc.Industry
NCT06181136 · 30 participants (planned) · Start Dec 7, 2023 · Primary completion Jul 2032
Drug: DNL126; Prophylactic immunomodulatory therapy · For: Mucopolysaccharidosis Type IIIA
Sites: Oakland, California; Iowa City, Iowa; Chapel Hill, North Carolina · 4 sites in all
Agios Pharmaceuticals, Inc.Industry
NCT07241234 · 20 participants (planned) · Start Apr 17, 2026 · Primary completion Jan 17, 2028
Drug: AG-181 · For: Phenylketonuria
Sites: Indianapolis, Indiana; Pittsburgh, Pennsylvania; Dallas, Texas · 5 sites in all
UniQure Biopharma B.V.Industry
NCT06270316 · 20 participants (planned) · Start Jun 5, 2024 · Primary completion Dec 1, 2027
Drug: AMT-191 · For: Fabry Disease
Sites: Birmingham, Alabama; Los Angeles, California; Atlanta, Georgia · 10 sites in all
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07446400 · 48 participants (planned) · Start Mar 31, 2026 · Primary completion Nov 7, 2026
Drug: Repinatrabit; EE/NE and 4 more · For: Healthy Volunteers
Sites: Melbourne, Australia
Otsuka Pharmaceutical Development & Commercialization, Inc.Otsuka
NCT07713758 · 32 participants (planned) · Start Jul 17, 2026 · Primary completion Feb 9, 2027
Drug: Repinatrabit · For: Phenylketonuria
Sites: Miami, Florida
Immusoft of CA, Inc.Industry
NCT05682144 · 11 participants (planned) · Start Apr 12, 2023 · Primary completion Jun 1, 2029
Drug: Autologous Plasmablasts (B cells) · For: Mucopolysaccharidosis IH/S; Mucopolysaccharidosis IS
Sites: Oakland, California; Minneapolis, Minnesota
- GenSci144 Tablets Phase I Clinical TrialRecruiting
Changchun GeneScience Pharmaceutical Co., Ltd.Industry
NCT07685210 · 48 participants (planned) · Start Jun 22, 2026 · Primary completion Sep 2026
Drug: GenSci144 tablets; GenSci144 placebo tablets · For: Phenylketonuria
Sites: Jinan, China
Chongqing Peg-Bio Biopharm Co., Ltd.Industry
NCT07672756 · 48 participants (planned) · Start Jul 20, 2025 · Primary completion Jun 1, 2027
Drug: PL54 · For: Phenylketonuria (PKU)
Sites: Hefei, China
- A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Clinical Trial)Recruiting
Aspa TherapeuticsIndustry
NCT04998396 · 26 participants (planned) · Start Sep 8, 2021 · Primary completion Oct 13, 2026
Drug: AAV9 BBP-812 · For: Canavan Disease
Sites: Oakland, California; Chicago, Illinois; Boston, Massachusetts · 4 sites in all
GC Biopharma CorpIndustry
NCT06858397 · 18 participants (planned) · Start May 14, 2025 · Primary completion Aug 30, 2028
Drug: HM15421/GC1134A · For: Fabry Disesase
Sites: Los Angeles, California; Kansas City, Kansas; Minneapolis, Minnesota · 10 sites in all
4D Molecular TherapeuticsIndustry
NCT05629559 · 18 participants (planned) · Start Oct 16, 2022 · Primary completion Jun 2026
Drug: 4D-310 · For: Fabry Disease
Sites: Melbourne, Australia; Perth, Australia; Westmead, Australia · 4 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.